These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 34462586)

  • 1. Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer.
    Marti JLG; Beckwitt CH; Clark AM; Wells A
    Br J Cancer; 2021 Oct; 125(9):1285-1298. PubMed ID: 34462586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins attenuate outgrowth of breast cancer metastases.
    Beckwitt CH; Clark AM; Ma B; Whaley D; Oltvai ZN; Wells A
    Br J Cancer; 2018 Oct; 119(9):1094-1105. PubMed ID: 30401978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.
    Baptista Moreno Martin AC; Tomasin R; Luna-Dulcey L; Graminha AE; Araújo Naves M; Teles RHG; da Silva VD; da Silva JA; Vieira PC; Annabi B; Cominetti MR
    Cell Oncol (Dordr); 2020 Oct; 43(5):915-929. PubMed ID: 32761561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
    Ghebeh H; Elshenawy MA; AlSayed AD; Al-Tweigeri T
    Immunotherapy; 2022 Mar; 14(4):189-199. PubMed ID: 34984928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
    Kyte JA; Røssevold A; Falk RS; Naume B
    J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biological agents in metastatic triple-negative breast cancer.
    Bramati A; Girelli S; Torri V; Farina G; Galfrascoli E; Piva S; Moretti A; Dazzani MC; Sburlati P; La Verde NM
    Cancer Treat Rev; 2014 Jun; 40(5):605-13. PubMed ID: 24529896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
    Amith SR; Wilkinson JM; Baksh S; Fliegel L
    Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
    Cabel L; Carton M; Pistilli B; Dalenc F; Vanlemnens L; Levy C; Jacot W; Debled M; Loeb A; Hennequin A; De la Motte Rouge T; Laborde L; Laurent C; Chamorey E; Parent D; Petit T; Mouret-Reynier MA; Campone M; Perrocheau G; Labreveux C; Bachelot T; Robain M; Lerebours F
    Breast; 2021 Apr; 56():18-25. PubMed ID: 33561617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.
    Chung WP; Yang CT; Chen HY; Su CY; Su HW; Ou HT
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):319-328. PubMed ID: 34006465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
    Mery B; Rowinski E; Vallard A; Jacquin JP; Simoens X; Magné N; Doucey P
    Oncology; 2019; 97(1):1-6. PubMed ID: 30939479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.